Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 6, 2012, Pages 630-636

  Salama, M M ^a   Mohamed Morad, A R ^a   Saleh, M A ^b   Sabri, N A ^a   Zaki, M M ^b   Elsafady, L A ^b  

^a Ain Shams University   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

acute coronary syndrome; aspirin; aspirin resistance; platelet aggregation; risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; THROMBOXANE B2;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ANTIPLATELET EFFECT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG DOSE TITRATION; DYSLIPIDEMIA; ELECTROCARDIOGRAM; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; HEMATOLOGY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LABORATORY TEST; LIPID ANALYSIS; LIVER FUNCTION; LOW DRUG DOSE; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OBESITY; SMOKING; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ADENOSINE DIPHOSPHATE; ASPIRIN; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOXANE B2;

EID: 84868334870     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01083.x     Document Type: Article

References (43)

1. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, (2002) ACC/AHA 2002 guideline updates for the management of patients with UA and non ST elevation myocardial infarction A report of the American College of Cardiology/American Heart Association Task Force Practice Guidelines (Committee on the Management of patients with UA). Journal of the American College of Cardiology, 40, 1366-1374.
2. Awtry EH, Loscalzo J, (2000) Aspirin. Circulation, 101, 1206-1218.
3. Tran HA, Anand SS, Hankey GJ, Eikelboom JW, (2007) Aspirin resistance. Thrombosis Research, 120, 337-46.
4. Feldman M, Jialal I, Devaraj S, (2001) Effects of low dose aspirin on serum C-reactive protein and thromboxane B2 concentrations. Journal of the American College of Cardiology, 37, 2036-2041.
5. Rugerri ZM, (1994) New insights into the mechanisms of platelet adhesion and aggregation. Seminars in Haematology, 31, 229-239.
6. Dacie AJ, Lewis FG, (2006). Practical haematology, 10th edn, London, Churchill Levingston, 320-322.
7. Allain CC, Poon LS, Chan CS, Richmond FU, Fu PC, (1974) Enzymatic determination of total serum cholesterol. Clinical Chemistry, 20, 470-475.
8. Burstein M, Scholnick HR, Morfix R, (1970) Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. Journal of Lipid Research, 11, 583-595.
9. Friedewald WT, Levy RJ, Fredrickson DS, (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ul-tracentrifuge. Clinical Chemistry, 18, 499-502.
10. Wahlefeld AW, Bergmeyer HU, (1974). Methods of enzymatic analysis 2nd English ed. New York NY: Academic Press Inc., 1831-1840.
11. Burrin JM, Price CP, (1985) Measurement of blood glucose. Annals of Clinical Biochemistry, 22, 327-332.
12. Coma-Canella I, Velasc A, (2007) Variability in individual responsiveness to aspirin: clinical implications and treatment. Cardiovascular and Hematological Disorders Drug Targets, 7, 274-287.
13. Gum PA, Kottke-Marchant K, Poggio ED, et al. (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. The American Journal of Cardiology, 88, 230-235.
14. Cotter G, Shemesh E, Zehavi M, et al. (2004) Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? American Heart Journal, 147, 293-300.
15. Chen WH, Cheng X, Lee PY, Ng W, Kwok JY, Tse HF, Lau CP, (2007) Aspirin resistance and adverse clinical events in patients with coronary artery disease. American Journal of Medicine, 120, 631-635.
16. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J, (2004). Antiplatelet effect of aspirin in patients with cerebrovascular disease, Stroke January 1, 35: 175-178
17. Hohlfeld T, Weber AA, Junghans U, Schumacher M, Boucher M, Schrör K, Siebler M, (2007) Variable platelet response to aspirin in patients with ischemic stroke. Cerebrovascular Diseases, 24, 43-50.
18. Roller RE, Dorr S, Pilger E, (2002) Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100. Blood Coagulation and Fibrinolysis, 13, 277-281.
19. Watala C, Ruzalski M, Golaoski J, Wieclawska B, Kropiwnickal A, Drzewoski J, (2006) Diabetic platelets are less sensitive to acetylsalicylic acid (Aspirin) the possible role of glycemic control. Biochemical Pharmacology, 45, 1343-1351.
20. Cambria-Kiely JA, Gandhi PJ, (2002) Possible mechanisms of aspirin resistance. Journal of Thrombosis and Thrombolysis, 13, 49-56.
21. Friend M, Vucenik I, Miller M, (2003) Platelet responsiveness to aspirin in patients with hyperlipidaemia. British Medical Journal, 326, 82-83.
22. Motovska Z, Sujanova Z, Wimmerova S, Ardo J, Skrakova M, Widimsky P, (2005) Comparison of cationic propyl gallate and adenosine diphosphate for the measurement of aspirin effectivity with optical aggregometry. Blood, 106, 142-146.
23. Hart RG, Leonard AD, Talbert RL, et al. (2003) Aspirin dosage and thromboxane synthesis in patients with vascular disease. Pharmacotherapy, 23, 579-584.
24. Malinin AI, Atar D, Callahan KP, et al. (2003) Effect of a single dose of aspirin on platelets in humans with multiple risk factors for coronary artery disease. European Journal of Pharmacology, 462, 139-143.
25. Zimmerman N, Kienzle P, Weber AA, Winter J, Gams E, Schrör K, Hohlfeld T, (2001) Aspirin resistance after coronary artery bypass grafting. Journal of Thoracic and Cardiovascular Surgery, 121, 982-984.
26. Ten Berg JM, Gerritsen WB, Haas FJ, Kelder HC, Verheugt FW, Plokker HW, (2002) High-dose aspirin in addition to daily low dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention. Thrombosis Research, 105, 385-390.
27. Malhotra S, Sharma YP, Grover A, et al. (2003) Effect of different aspirin doses on platelet aggregation in patients with stable coronary artery disease. Internal Medicine Journal, 33, 350-354.
28. Lee PY, Chen WH, Ng W, et al. (2005) Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. The American Journal of Medicine, 118, 723-727.
29. Cooke CE, Liu-Stratton Y, Frid DJ, Magorian RD, Bray PF, Goldschmeidt-Clermont PJ, (2001) Pharmacogenomics: response to aspirin is dose, agonist and PLA dependent. Journal of the American College of Cardiology, 37 (Suppl. A), 1A-648A.
30. Rozaleski M, Boncler M, Luzak B, Watala C, (2005) Genetic factors underlying differential blood platelet sensitivity to inhibitors. Pharmacological Reports, 57, 1-13.
31. Helgason CM, Bolin KM, Hoff JA, et al. (1994) Development of aspirin resistance in persons with previous ischemic stroke. Stroke, 25, 2331-2336.
32. MacDonald TM, Wei L, (2003) Effect of ibuprofen on cardioprotective effect of aspirin. Lancet, 361, 573-4.
33. 2 and prostacyclin. Stroke, 32, 1400-1404.
34. Altman R, Scazziota A, Cordero Funes J, (1988) Why single daily dose of aspirin may not prevent platelet aggregation. Thrombosis Research, 51, 259-266.
35. Altman R, Luciardi HL, Muntaner J, Herrera RN, (2004) The antithrombotic profile of aspirin: aspirin resistance, or simply failure? Thrombosis Journal, 2, 1.
36. Cattaneo M, (2004) Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 1980-1987.
37. Andersen K, Hurlen M, Arnesen H, Seljeflot I, (2003) Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thrombosis Research, 108, 37-42.
38. Dalen JE, (2007) Aspirin resistance: is it real? Is it clinically significant? American Journal of Medicine, 120, 1-4.
39. Michelson AD, Furman MI, Goldschmidt-Clermont P, (2000) Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation, 101, 1013-1018.
40. Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F, (2004) Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. Journal of the American College of Cardiology, 43, 979-984.
41. Nicholson NS, Panzer-Knodle SG, Haas NF, et al. (1998) Assessment of platelet function assays. American Heart Journal, 135, S170-S178.
42. Patrono C, Rocca B, (2008) Aspirin: promise and resistance in the new millennium. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, S25-S32.
43. Martin CP, Talbert RL, (2005) Aspirin resistance: an evaluation of current evidence and measurement methods. Pharmacotherapy, 25, 942-953.